

PTO/SB/08A (07-05)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary.)

Sheet 1

of 3

Complete if Known	
Application Number	10/723,570
Filing Date	November 24, 2003
First Named Inventor	John M. Pawelek
Art Unit	1636
Examiner Name	Jennifer Ann Dunston
Attorney Docket Number	869-BAZ-US

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Donald J. Cook

Date Considered

3/24/2020

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **¹**Applicant's unique citation designation number (optional). **²**See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. **³**Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **⁴**For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **⁵**Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **⁶**Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/723,570
		Filing Date	November 24, 2003
		First Named Inventor	John M. Pawelek
		Art Unit	1636
		Examiner Name	Jennifer Ann Dunston
Sheet	2	of	3
		Attorney Docket Number	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
JP	2	BISNO, Chapters 175-176, Principles and Practice of Infectious Disease (3rd ed.) 1518-1527 (1990)		T ²
JP	3	BRENNER, Facultatively anaerobic gram-negative rods, Bergey's Manual of Systematic Bacteriology 1:408-506 (1984)		
JP	4	COLEY, W., The treatment of malignant tumors by repeated inoculations of erysipelas, Clin. Orthop. 262:3-11 (1991)		
JP	5	DINARELLO, C., et al., Blocking IL-1:Interleukin-1 receptor antagonist in vivo an in vitro, Immunology Today 12(11):404-410 (1991)		
JP	6	GALANOS, C., et al., A new method for the extraction of R. lipopolysaccharides, European J. Biochem. 9:245-249 (1969)		
JP	7	HUBER, B., et al., Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase, Proc. Natl. Acad. Sci. USA 91:8302-8306 (1994)		
JP	8	KELLY, T., et al., The firA gene of Escherichia coli encodes UDP-3-O-(R-3-hydroxymyristoyl)-glucosamine N-Acyltransferase, J. Biol. Chem. 268:19866-19874 (1993)		
JP	9	LITTER, E., et al., Human cytomegalovirus UL97 open reading frame encodes a protein that phosphorylates the antiviral nucleoside analogue ganciclovir, Nature 358:160-162 (1992)		
JP	10	RAETZ, C., Bacterial endotoxins: Extraordinary lipids that activate eucaryotic signal transduction, J. Bacteriol. 175:5745-5753 (1993)		
JP	11	ROMICK, et al., Aerobic and anaerobic metabolism of Listeria monocytogenes in defined glucose medium, Appl. Environ. Microbiol. 62(1):304-307 (1996)		

Examiner Signature		Date Considered	3/24/2006
--------------------	---	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
		Application Number	10/723,570
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	November 24, 2003
(Use as many sheets as necessary)		First Named Inventor	John M. Pawelek
		Art Unit	1636
		Examiner Name	Jennifer Ann Dunston
Sheet	3	of	3
		Attorney Docket Number	869-BAZ-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
JP	12	ROY, A. and COLEMAN, J., Mutations in firA, Encoding the Second Acyltransferase in Lipopolysaccharide Biosynthesis, Affect Multiple Steps in Lipopolysaccharide Biosynthesis, J. Bacteriol. 176(6):1639-1645 (1994)	Duplicate citations
JP	13	SIMONEN, M., et al., Protein secretion in Bacillus species, Microbiol. Reviews 57(1):109-137 (1993)	
JP	14	SMITH and GOODMAN, Improved culture method for the isolation of Histoplasma capsulatum and Blastomyces dermatitidis from contaminated specimens, Am. J. Clin. Pathol: 63:276-280 (1975)	
JP	15	SULLIVAN, V., et al., A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells, Nature 358:162-164 (1992)	
JP	16	TAYLOR-ROBINSON, Ureaplasma urealyticum (T-strain mycoplasma) and Mycoplasma hominis, Principles and Practice of Infectious Diseases (3rd ed.) 1458-1463 (1990)	
JP	17	VICKERMAN, Phylum Zoomastigina, Handbook of Protocista 215-238 (1990)	
JP	18	VIVIER and DESPORTES, Phylum Apicomplexa, Handbook of Protocista 549-573 (1990)	
JP	19	WALZER, Pneumocystis carni, Principles and Practice of Infectious Diseases (3rd ed.) x-xi and 2103-2109 (1990)	

Examiner Signature	<i>Jennifer Ann Dunston</i>	Date Considered	3/24/2006
--------------------	-----------------------------	-----------------	-----------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.